A multicenter retrospective analysis of 174 NSCLC patients demonstrated an ORR to PD-1 blockade which differed significantly among subgroups with STK11/LKB1 co-mutations (7.4%), TP53 co-mutations (35.7%), and KRASm patients without these alterations (28.6%) [p < 0.001] [32] A significantly shorter mOS was seen in the STK11/LKB1-mutant compared to wild-type tumors (HR 1.99, 95% CI 1.29 to 3.06; [p = 0.0015]) [32]. This evidence concerns the gene STK11 and non-small cell lung carcinoma.